All biotech companies engage in spin, but the degree varies widely. What RVNC might be doing with its 100U-vial explanation for the BLA-submission delay is relatively benign spin, if my reading of the situation is correct.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”